'A Decade after The Decade of the Brain' series

In 1990, Congress designated the 1990s the “Decade of the Brain.” President George H. W. Bush proclaimed, “A new era of discovery is dawning in brain research.” During the ensuing decade, scientists greatly advanced our understanding of the brain.

The editors of Cerebrum asked the directors of seven brain-related institutes at the National Institutes of Health (NIH) to identify the biggest advances, greatest disappointments, and missed opportunities of brain research in the past decade—the decade after the “Decade of the Brain.” We also asked them what looks most promising for the coming decade, the 2010s. Our experts focused on research that might change how doctors diagnose and treat human brain disorders.

[Complete collection (PDF)]

Thursday, Feb. 18: Nora D. Volkow, M.D., National Institute on Drug Abuse 

Friday, Feb. 19: Thomas R. Insel, M.D., National Institute of Mental Health 

Monday, Feb. 22: Story Landis, Ph.D., National Institute of Neurological Disorders and Stroke 

Tuesday, Feb. 23: Kenneth R. Warren, Ph.D., National Institute on Alcohol Abuse and Alcoholism 

Wednesday, Feb. 24: Paul A. Sieving, M.D., Ph.D., National Eye Institute

Thursday, Feb. 25: James F. Battey Jr., M.D., Ph.D., National Institute on Deafness and Other Communication Disorders 

Friday, Feb. 26: Richard J. Hodes, M.D., National Institute on Aging 

Wednesday, February 24, 2010

Using Breakthroughs in Visual Neuroscience to Treat Diseases

A Decade after The Decade of the Brain

By: Paul A. Sieving, M.D., Ph.D.

In this seven-part series, directors of neuroscience-related institutes at the National Institutes of Health examine how brain research has progressed since 2000—the decade after The Decade of the Brain. Here in part five, we hear from Paul A. Sieving, M.D., Ph.D., of the National Eye Institute.

 Sieving Headshot - Thumbnail

Advances in visual neuroscience during the past 10 years are generating a lot of excitement. The ability to record simultaneously the activity of different clusters of neurons in the eye has greatly improved our understanding of how our neural circuits process and integrate visual signals. For example, recording the impulses from clusters of retinal ganglion cells, which transmit visual input from the eye to the brain, allows researchers to characterize completely the information presented to the visual parts of the brain.

The next research front will involve investigating how neurons interconnect into circuits that control visually guided behavior, such as when we alter our path to avoid an obstacle we see. In the next decade, three recent technical advances will help us learn more about this neural circuitry. First, scientists can now see complex, interconnected brain structures using the Brainbow technique, which employs genetically coded fluorescent proteins that can mark hundreds of neurons with unique colors. Second, two-photon imaging technology can display the dynamic interactions between neurons in real time. Finally, scientists can implant into the brain a grid containing 100 electrodes that deliver signals to a computer, which measures the activity of individual neurons within a larger group.

Scientists can use information about the activity of individual neurons therapeutically. Because the organization of the primate visual system is very close to that of humans, what we learn through ethical studies of nonhuman primates brings us closer to human medical applications. Studies using an array of electrodes implanted in the brain show that monkeys can use their visual system to control an artificial limb remotely, by mental control alone.1 If this ability holds true in humans, it could dramatically improve sensory substitution treatments used for a range of human injuries—for example, better devices for people who have lost limbs due to war or disease. In addition, learning about faulty nerve circuits in the visual system will provide insight into other types of circuit disorders, such as chronic pain and epilepsy.

We have tremendous opportunities to translate what we have learned about visual circuits in the past decade into treatments for neurodegenerative diseases affecting vision, such as retinitis pigmentosa and macular degeneration. These diseases target photoreceptor cells in the retina, which normally process light that becomes an image when electrochemical signals are transmitted through the retina and optic nerve to the brain. The degeneration or death of photoreceptor cells causes loss of vision and blindness, but the other parts of the transmission process—the second-stage retinal neurons—remain intact. Researchers are testing several methods to activate retinal cells by bypassing the nonfunctional photoreceptor cells.

For example, through funding from the National Eye Institute and the U.S. Department of Energy, scientists have developed an artificial retina chip—an electrode array that receives signals interpreted as electrical impulses from a camera. When the array is transplanted into the eye, it stimulates the remaining retinal circuits and transmits the impulses to the brain to enable it to visualize what the camera sees. An alternative strategy involves a microchip with tiny solar cells that convert light energy into electrochemical impulses. And optogenetics, which draws on advances in nanotechnology, uses pulses of light to specifically activate genetically engineered ion channels in retinal cells to initiate the visual pathway.

Researchers are also investigating how to restore vision via cell-based therapies such as stem cell technology and gene therapy. For example, scientists can now induce stem cells to develop into retinal cells, and these cells function correctly when transplanted into an animal with retinal degeneration. The most promising results come from recent clinical trials using gene therapy to treat people with Leber’s congenital amaurosis. People with this condition lack an enzyme required for vitamin A metabolism, and the resultant degeneration of photoreceptor cells causes vision loss. When researchers delivered the missing enzyme to the remaining intact photoreceptors, the patients’ visual sensitivity increased. This was one of the first examples of safe and effective gene therapy.

These advances are beginning to help people with limited vision see better. They are also shedding light on treatments for other neurological disorders. New technologies and scientific breakthroughs afford significant opportunities to expand our knowledge about the visual system and develop applications with therapeutic potential.


1.  M. Velliste, S. Perel, M. C. Spalding, A. S. Whitford, and A. B. Schwartz, “Cortical Control of a Prosthetic Arm for Self-feeding,” Nature 453, no. 7198 (2008): 1098–1101.

About Cerebrum

Bill Glovin, editor
Carolyn Asbury, Ph.D., consultant

Scientific Advisory Board
Joseph T. Coyle, M.D., Harvard Medical School
Pierre J. Magistretti, M.D., Ph.D., University of Lausanne Medical School and Hospital
Helen Mayberg, M.D., Icahn School of Medicine at Mount Sinai 
Bruce S. McEwen, Ph.D., The Rockefeller University
Donald Price, M.D., The Johns Hopkins University School of Medicine
Charles Zorumski, M.D., Washington University School of Medicine

Do you have a comment or question about something you've read in CerebrumContact Cerebrum Now.